Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Caduet Launch Set For May; Inspra Starts Slow

Executive Summary

Pfizer will position the Lipitor/Norvasc combination product Caduet as an "upgrade" for the vast majority of hypertension patients, rather than focus on cannibalizing Norvasc, the company told analysts during an April 20 earnings conference call

You may also be interested in...



Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable

The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel